Biotech R&D Insurance

Protecting discovery- and pre-clinical-stage biotechnology companies

Biotech R&D companies carry a risk profile that looks nothing like a normal business, because their value sits almost entirely in things that never appear on a traditional policy — a research pipeline, a patent position, a library of irreplaceable cell lines and samples, the data behind years of experiments, and the scientists who hold it all in their heads. Most are pre-revenue and venture-funded, which leads founders to assume there is little to insure. In reality the exposures that can end an early-stage biotech are concentrated and severe: the catastrophic loss of research or samples, a dispute with investors over governance or a failed round, an intellectual-property fight over the pipeline, and the biohazard and professional exposures of running a working lab. This class builds on life sciences fundamentals but belongs to the earliest stage of the lifecycle, before products liability and commercial manufacturing dominate the picture.

Properly built coverage protects the science, the investment behind it, and the people doing the work — long before there is anything to sell.

The Biotech R&D Company's Signature Exposures

The defining exposure is the irreplaceable nature of the research itself. A freezer failure, contamination event, or fire can destroy cell lines, reagents, and a sample biobank that represent years of work and cannot simply be rebought — and the business-interruption loss that follows can be existential for a company with no revenue to fall back on. Running alongside it is management liability: venture-funded biotechs face directors-and-officers exposure from investors, board decisions, and funding rounds well before they face a patient. Professional and technology errors in research, data, and software, intellectual-property disputes over the pipeline, and the biohazard and pollution exposures of a working laboratory round out a profile where the threats are real long before a product exists.

Key Risks in Biotech R&D Operations

Biotech R&D companies face exposure related to:

Catastrophic loss of cell lines, samples, reagents, or a biobank from equipment failure or contamination

Business interruption when a destroyed experiment or lab stops the research for months

Investor, governance, and funding disputes at a venture-backed company

Intellectual-property, patent, and licensing conflicts over the pipeline

Errors in research, data, bioinformatics, or software that others rely on

Biohazard, chemical, and pollution exposures from laboratory operations

Injury to employees handling biologics, chemicals, and specialized equipment

The loss that defines this stage is destroyed research or a dispute that cuts off funding — not a product claim.

Core Coverages for Biotech R&D Companies

A properly built biotech R&D program typically includes:

Directors & Officers Liability — Protects the board and executives over governance, funding, and investor exposure — often the first real liability a venture-backed biotech faces.

Professional / Technology E&O — Covers errors in research, data, bioinformatics, and software-driven tools that others rely on.

Commercial Property & Equipment Breakdown — Insures labs, clean rooms, freezers, and specialized instruments, including the equipment-breakdown failure that spoils temperature-sensitive materials.

Research & Property of Others / Valuable Papers — Covers cell lines, samples, reagents, and sponsor-owned materials in your care, to the extent they can be valued and replaced.

Business Interruption & Extra Expense — Replaces income and funds the cost of resuming research after a covered loss halts the lab.

Pollution & Biohazard Liability — Responds to contamination, biological, and chemical exposures a general policy excludes.

Clinical Trial Liability — Adds human-subject coverage once the company reaches first-in-human studies.

Cyber & Privacy — Protects research data, genomic information, and connected lab systems from breach and loss.

Workers' Compensation — Provides legally required coverage for scientists and staff across lab and office operations.

What's Commonly Overlooked

Biotech R&D programs are most often weakened by:

A generic business owners policy that excludes biohazard, the specialized lab property, and the real exposures

D&O left unbought because the company is "pre-revenue," despite active investors and a board

No valuation or coverage for irreplaceable cell lines, samples, and reagents

Equipment-breakdown and spoilage limits too low for a freezer or clean-room failure

Intellectual-property exposure over the pipeline left entirely uninsured

The gap that hurts most is treating a pre-revenue company as low-risk when a destroyed biobank or an investor suit can end it.

Real-World Claim Examples

A freezer fails over a weekend and destroys an irreplaceable cell line and sample library

A fire or contamination event halts research for months at a company with no revenue

Investors sue the board after a funding round collapses or a program is shelved

A collaborator alleges the company's data or research caused a downstream loss

A patent or licensing dispute erupts over the ownership of the pipeline

Any one of these can threaten the company's survival long before it has a product on the market.

Regulatory & Compliance Context

Even before a product exists, biotech R&D operates inside a regulatory and biosafety framework. Laboratories handling biological agents follow CDC and NIH biosafety-level standards and, where recombinant or synthetic nucleic acids are involved, the NIH Guidelines; OSHA's laboratory and bloodborne-pathogen standards govern worker safety; and select agents are controlled under federal law. As the company approaches human testing, it enters the FDA's orbit through the investigational new drug (IND) pathway and Good Laboratory Practice for pre-clinical studies. Investors and partners expect this discipline in place, and a documented biosafety and quality posture is central to both insurability and the next funding round.

Why Proper Placement Matters

Stage is everything in biotech. A discovery-stage company, a pre-clinical company preparing an IND, and one entering first-in-human trials carry different exposures and belong on different programs — and the program has to grow with the science. Underwriters weigh the research area and biosafety level, the lab and its critical equipment, the funding structure and investor profile, the intellectual-property position, and how close the company is to the clinic. Much of this risk — management liability, biohazard, and specialized property — is written in specialty and excess-and-surplus-lines markets that understand emerging science and venture-backed balance sheets. Presenting disciplined biosafety, clear governance, and a documented valuation of critical research is what opens appetite at a stage many generic carriers avoid.

Our Approach

At Cory Washington & Co., we build biotech R&D programs around where the company actually is in its lifecycle — prioritizing the management liability, specialized property, biohazard, and professional exposures that threaten a pre-revenue company, and adding clinical trial coverage as the science reaches the clinic. We access the specialty and E&S markets built for emerging biotech, document the value of irreplaceable research so it can actually be covered, and scale the program with each round. We also insure related businesses, including the broader life sciences company, contract research organizations, and diagnostics and genomics labs.

The product may be years away — but the risk is here now, and we build coverage that protects the science from the first experiment.

All insurance descriptions on this website are provided by Cory Washington & Co. LLC strictly for general informational purposes. They are not intended to be, and should not be relied upon as, legal, financial, or insurance advice. The information presented is general in nature and does not guarantee the availability, terms, conditions, or scope of any insurance coverage. Actual coverage is determined solely by the specific policy language issued by the insurer and remains subject to underwriting approval. Nothing on this website creates or implies an agent-client relationship, binds coverage, or alters any existing policy. Cory Washington & Co. LLC expressly disclaims any liability for actions taken, or not taken, based on the content provided here. For advice regarding your particular situation, please consult directly with a licensed insurance professional at Cory Washington & Co. LLC or another qualified insurance professional, and always review your policy documents in full.

Frequently Asked Questions

Available in all 50 states. See how requirements differ in California, Texas, Florida, New York, or choose your state.